XRCC1 and neoplasm: Low levels of XRCC1 expression have generally been associated with increased tumour aggressiveness and poorer outcome in triple negative breast cancer [41], reduced survival in gastric cancer [42] and unresponsiveness to radiotherapy in bladder cancer [43].